Regulatory Considerations for Antibody-Drug Conjugates From the Small Molecule Perspective
Time: 9:30 am
day: Day One
Details:
- Overview of the review process for ADC products, with a focus on the small molecule
- Review expectations on payload-linker controls
- Discuss the expectations on DAR and residual impurities controls in the ADC drug substances and drug products
